For CD9, its study in glioblastoma multiforme (GBM) revealed that the increase of CD9 and CD81 in extracellular vesicles (EVs) after radiotherapy was closely related to the cytotoxic response after treatment, which provided a new biomarker for radiotherapy monitoring (Jennrich et al., 2022). This evidence concerns the gene CD9 and glioblastoma.